Type 2 diabetes occurs when the β-cells do not secrete enough insulin to counter balance insulin resistance. Mc Wherter, 2010The discovery of novel agonists of GPR119 receptor for the treatment of type 2 diabetes. Lixisenatide is a new potent and selective GLP-1 receptor agonist currently in development. Intensive treatment of glycaemia reduces microvascular complications, especially retinopathy and nephropathy, but has only a modest effect in reducing macrovascular complications. A Bayesian NMA was conducted. However, pre-index anti-diabetic therapy differed between the countries. Change in weight from baseline was comparable for all GLP-1 RAs.
The GLP-1 receptor agonists have proven efficacy in the treatment of type 2 diabetes and may provide patients with additional nonglycemic benefits, including significant weight loss and decreased systolic blood pressure. Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean